Bristol-Myers Squibb has cleared Q2 and the setup has flipped — the shorts that were rebuilding ahead of the July 30 print are now unwinding, while a wave of analyst upgrades and target hikes is pushing the stock to $65.89, up 13% over the past month.
The short interest reversal is direct confirmation of what that pre-earnings rebuild was: a hedged bet into results, not a structural position. Short interest as a percentage of the free float has dropped from roughly 2.4% on July 28 to 2.3% on August 4, with borrowed shares falling nearly 6% over the week from ~49.6 million to ~46.2 million. The borrow market remains essentially open. Availability is running at over 8,000% of current short interest — meaning for every share currently lent out, more than 80 are available in the lending pool. Cost to borrow has moved up 50% on the week to 0.56%, but in absolute terms that figure is still trivially low; the move tracks the post-earnings price rise more than any fresh demand from short sellers. The ORTEX short score has drifted down to 34.3, its lowest reading in the observed window, consistent with bears on the back foot.
The analyst response to Q2 was emphatic and broad-based. Multiple firms raised targets on July 31, the day after results. JP Morgan lifted its Overweight target from $67 to $73. Guggenheim moved its Buy target from $72 to $75. Truist and Wells Fargo both raised targets while holding constructive ratings. Then on August 5, Argus Research upgraded the stock outright from Hold to Buy with a $75 target — the freshest and most directional move in the pack. Citigroup, which stays Neutral, still raised its target from $66 to $70. The only outlier in recent weeks was Bank of America, which trimmed its Buy target marginally in July and has not yet responded to the earnings print. Consensus sits at hold — 7 buys against 17 holds — which means the upgrade cycle has room to run if Q3 guidance holds. The mean price target from buy-side bulls now clusters in the $70–75 range, while the stock at $65.89 still trades at a discount to even the more cautious of those numbers.
The bull and bear cases post-results remain structurally similar to pre-earnings but the balance of evidence has shifted. Bulls point to growth products and Eliquis trajectory, with the Q2 print apparently providing enough confidence that multiple analysts moved numbers higher in the same session. Bears retain their standard playbook — competition in cardiovascular and oncology, clinical failure risk in the pipeline, and Revlimid genericization as a slow revenue drag. The factor scores offer modest support to the bull case: EPS momentum at both 30 and 90 days ranks in the upper half of the universe (83rd and 66th percentiles respectively), and the dividend score ranks at the 99th percentile, underlining the yield case for income-oriented holders. The P/E running at roughly 9.9x and EV/EBITDA near 9.1x — both up meaningfully over 30 days — suggest the re-rating is already underway but multiples remain undemanding by pharma standards.
Against peers, BMY is the clear outperformer this week. MRK slipped nearly 3% over the same period. PFE was the only large-cap pharma name that also gained, up about 0.6%. LLY fell more than 8% on the week, and JNJ dropped over 4%. The divergence reflects how specifically the Q2 beat was received — this was a BMY-specific catalyst, not a sector tide.
The next earnings event is pencilled in for October 29. Between now and then, the question worth tracking is whether the analyst consensus migrates further toward buy — seven buys against seventeen holds leaves meaningful room for upgrades if the growth product trajectory extends into Q3 — and whether the shorts that exited post-results return as the stock approaches the $70–75 target cluster the bulls are now defending.
See the live data behind this article on ORTEX.
Open BMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
